exposing Parkinson's disease's voices and faces.

Published Date: 26 Apr 2023

One million Americans currently have Parkinson's disease, and another 90,000 are diagnosed with it each year. It is currently the second most prevalent neurodegenerative disease in the country. And it's moving up to No. 1. However, few people are familiar with Parkinson's.

Read Full News

Latest News

This Week on NeurologyLive® — October 26, 2026 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Calcium Channel Blockers Linked to Lower Blood Pressure Variability Marco Meglio

A target trial emulation pooling ACCORD-BP and SPRINT data found calcium channel blocker regimens reduced blood pressure variability without changing cardiovascular outcomes.

CAR-T Agent Zola-cel Shows No New Multiple Sclerosis Disease Activity in Phase 1 Study Louie Pasculli

Updated data from Breakfree-2 study showed that treatment with a single zola-cel infusion achieved NEDA-3 in highly active relapsing multiple sclerosis and led to mostly stable disability in progressive multiple sclerosis.

NeurologyLive® Brain Games: October 25, 2026 Louie Pasculli, Marco Meglio

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is recent advances in gene therapies.

Tenecteplase Benefit Before Thrombectomy Varies by Stroke Cause, Study Shows Marco Meglio

A secondary analysis of the BRIDGE-TNK trial found tenecteplase before thrombectomy improved functional outcomes in cardioembolic but not atherosclerotic stroke.

Houston Forum Highlights Awareness Gaps in NF1 Plexiform Neurofibroma Care Marco Meglio

At a NeurologyLive and Targeted Oncology Clinical Forum in Houston, Kevin J. Bielamowicz, MD, of Arkansas Children’s Hospital, discussed how incidental diagnosis and limited awareness of systemic therapy continue to delay care for patients with NF1-associated plexiform neurofibromas.

Todays Updates

Phase 2 ACUITY Analysis Shows Privosegtor Associated With Smaller Early NfL and GFAP Increases in Acute Optic Neuritis Isabella Ciccone, MPH

New biomarker data showed smaller post-onset increases in plasma neurofilament light chain and glial fibrillary acidic protein with privosegtor added to steroids in patients with acute optic neuritis.

CORE-VNS Study Shows Sustained Seizure Reduction With VNS Therapy at 36 Months Louie Pasculli

The 36-month CORE-VNS study findings showed sustained seizure reduction, improved quality of life, and reduced seizure-related hospitalizations among people with drug-resistant epilepsy receiving vagus nerve stimulation therapy.

The Expanding Role of Blood-Based Biomarkers in MS Care Louie Pasculli, Terrie Livingston, PharmD

Terry Livingston, PharmD, vice president of medical affairs at Octave Bioscience, discussed the evolving role of blood-based biomarkers in multiple sclerosis care.

Matching CKD Education to Patient Readiness for Home Dialysis, With Christopher Chan, MD

Matching CKD Education to Patient Readiness for Home Dialysis, With Christopher Chan, MD

Upacicalcet Lowers PTH in Secondary Hyperparathyroidism on Hemodialysis

Upacicalcet Lowers PTH in Secondary Hyperparathyroidism on Hemodialysis

Tradipitant Cuts Semaglutide-Induced Vomiting in Phase 3 Trial

Tradipitant Cuts Semaglutide-Induced Vomiting in Phase 3 Trial

Todays Updates

Phase 2 ACUITY Analysis Shows Privosegtor Associated With Smaller Early NfL and GFAP Increases in Acute Optic Neuritis Isabella Ciccone, MPH

New biomarker data showed smaller post-onset increases in plasma neurofilament light chain and glial fibrillary acidic protein with privosegtor added to steroids in patients with acute optic neuritis.

CORE-VNS Study Shows Sustained Seizure Reduction With VNS Therapy at 36 Months Louie Pasculli

The 36-month CORE-VNS study findings showed sustained seizure reduction, improved quality of life, and reduced seizure-related hospitalizations among people with drug-resistant epilepsy receiving vagus nerve stimulation therapy.

The Expanding Role of Blood-Based Biomarkers in MS Care Louie Pasculli, Terrie Livingston, PharmD

Terry Livingston, PharmD, vice president of medical affairs at Octave Bioscience, discussed the evolving role of blood-based biomarkers in multiple sclerosis care.

Matching CKD Education to Patient Readiness for Home Dialysis, With Christopher Chan, MD

Matching CKD Education to Patient Readiness for Home Dialysis, With Christopher Chan, MD

Upacicalcet Lowers PTH in Secondary Hyperparathyroidism on Hemodialysis

Upacicalcet Lowers PTH in Secondary Hyperparathyroidism on Hemodialysis

Tradipitant Cuts Semaglutide-Induced Vomiting in Phase 3 Trial

Tradipitant Cuts Semaglutide-Induced Vomiting in Phase 3 Trial

Latest News

Here's some of what is coming soon to NeurologyLive® this week.

A target trial emulation pooling ACCORD-BP and SPRINT data found calcium channel blocker regimens reduced blood pressure variability without changing cardiovascular outcomes.

Updated data from Breakfree-2 study showed that treatment with a single zola-cel infusion achieved NEDA-3 in highly active relapsing multiple sclerosis and led to mostly stable disability in progressive multiple sclerosis.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is recent advances in gene therapies.

A secondary analysis of the BRIDGE-TNK trial found tenecteplase before thrombectomy improved functional outcomes in cardioembolic but not atherosclerotic stroke.

At a NeurologyLive and Targeted Oncology Clinical Forum in Houston, Kevin J. Bielamowicz, MD, of Arkansas Children’s Hospital, discussed how incidental diagnosis and limited awareness of systemic therapy continue to delay care for patients with NF1-associated plexiform neurofibromas.

News All Time

FDA Grants Fast Track to AV-1959R for Alzheimer Prevention Matt Hoffman

Fast Track status covers AV-1959R, an investigational amyloid-beta vaccine, for preventing Alzheimer disease in cognitively unimpaired adults with amyloid pathology.

Early Data Show Dual-Targeting CAR-T Agent CTA313 Stabilizes Progressive Multiple Sclerosis Marco Meglio

Early phase 1 data in 3 patients suggest CTA313, an allogeneic CD19/BCMA CAR-T, may stabilize disability with a manageable safety profile in progressive MS.

Divozilimab Cuts Relapse Risk at 1 Year in Phase 3 AQUARELLE Trial of NMOSD Marco Meglio

One-year data from the phase 3 AQUARELLE study found that divozilimab, an anti-CD20 antibody, reduced relapse risk in patients with neuromyelitis optica spectrum disorder.

Clene Submits NDA Seeking Accelerated Approval for ALS Drug Marco Meglio

Clene has filed an NDA seeking accelerated approval of CNM-Au8 for ALS, following 2 missed primary trial endpoints and years of evolving FDA guidance.

Real-World Data Back Stiripentol’s Effect on Seizures in Dravet Syndrome Marco Meglio

A retrospective 10-center U.S. study found stiripentol reduced convulsive seizure frequency, status epilepticus episodes, and emergency health care use in patients with Dravet syndrome.

Diazepam Nasal Spray Terminates Most Pediatric Status Epilepticus Episodes in Seizure Clusters, Post Hoc Analysis Shows Isabella Ciccone, MPH

Newly presented post hoc analyses examined diazepam nasal spray for status epilepticus in seizure clusters and intervals between clusters in children, alongside real-world data on rescue medication prescribing.

Amyloid Vaccine AV-1959R Generates Antibodies in All Phase 1 Recipients Louie Pasculli

In a 16-person placebo-controlled trial, every cognitively unimpaired adult given AV-1959R developed anti-amyloid-beta antibodies, while placebo recipients stayed at baseline.

Decade of OPERA Data Supports Early Ocrelizumab Treatment Initiation in Relapsing Multiple Sclerosis Isabella Ciccone, MPH

A newly published 10-year analysis of the OPERA I and II trials reported that starting ocrelizumab 2 years earlier was associated with less disability accrual in relapsing MS, with no new safety signals.

This Week on NeurologyLive® — October 19, 2026 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Ocrelizumab Shows MRI Benefits vs Fingolimod in Phase 3 Pediatric-Onset Multiple Sclerosis Study Louie Pasculli

Ocrelizumab demonstrated noninferiority to fingolimod for relapse control but displayed greater reductions in MRI lesion activity among pediatric patients with relapsing-remitting multiple sclerosis.

NeurologyLive® Brain Games: October 18, 2026 Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is biomarkers in multiple sclerosis!

First-in-Human Trial Begins for an Antisense Oligonucleotide in KCNT1-Related Epilepsy Marco Meglio

A phase 1b/2 trial is testing an intrathecal antisense oligonucleotide designed to lower KCNT1 expression in children with a severe, drug-resistant epilepsy syndrome.

NeurologyLive® Friday 5 — October 16, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 16, 2026.

RGX-202 Meets Primary End Point in Phase 3 Duchenne Trial Louie Pasculli

Pivotal AFFINITY DUCHENNE results showed microdystrophin expression above the prespecified threshold in 93% of evaluable participants, with preliminary functional findings favoring treatment over external controls.

Nipocalimab in Myasthenia Gravis: Real-World Use, Long-Term Safety, and the Road Ahead Marco Meglio, Leonard Dragone, MD, PhD

Leonard Dragone, MD, PhD, Disease Area Leader at Johnson & Johnson, discusses how nipocalimab is being incorporated into generalized MG care, what long-term data show, and where J&J sees the therapy’s role evolving.

FDA Approves Autoinjector for Self-Administered Zilucoplan in Generalized Myasthenia Gravis Marco Meglio

Adults with generalized myasthenia gravis who are anti-acetylcholine receptor antibody positive now have a second self-administration option for the complement inhibitor zilucoplan.

Recommended News For You

Dasatinib Fails to Improve Outcomes in CBF-AML

Three-Drug Regimens Make Case for a Role in Untreated and Relapsed/Refractory CLL

Genetics and Genetic Testing to Inform Myelofibrosis Clinical Management.

Laryngeal Transplant Helped a Cancer Patient Speak Again in Pioneering Study

As compared to proton therapy, proton therapy is very effective in treating esophageal cancer.

Effective Intralesional Melanoma Therapy May Involve Systemic Effects.

Why preventive mastectomy isn't offered to everyone at risk

Recommended Articles For You

Ferroptosis as a Therapeutic Target in Cancer 

Circulating Tumor DNA Dynamics for Therapy Matching: A Comprehensive Clinical Review 

Cemiplimab: A Revolutionary Drug For Treating Cancer 

Advancements in Survival Mechanisms and Prognostic Determinants in Acute Myeloid Leukemia 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

New drug combination shows good results in patients with HPV-negative head and neck cancer

2.

Increasing Access to Prostate Cancer Drugs; Reducing Toxic Emissions; FTC Files a 'Charity' Suit.

3.

Asian Women With Breast Cancer Outlive White Peers

4.

What Comes After Cancer?

5.

An Examine More Into the Acceptance of CRISPR/Cas9 Gene Therapy for Sickle Cell Illness.

1.

Understanding Acute Intermittent Porphyria: Symptoms, Diagnosis and Treatment

2.

Spatial Transcriptomics in Oncology: Transforming Tumor Biology and Precision Medicine

3.

Inside Oncology Trials: From Protocol to Progress in Cancer Research and Care

4.

Endurance Training in Hematologic Disease: Current Perspectives and Clinical Implications

5.

Cowden Syndrome and Cancer: Understanding the Risk Factors 

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

Unmet Needs in ALK Positive NSCLC- The Challenges in the Current Care

2.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part II

3.

Understanding Common Causes of Abnormal Blood Counts

4.

Efficient Management of First line ALK-rearranged NSCLC - Part VIII

5.

Diagnosis and Management in Hematology

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot